Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials

Fig. 3

Percentage of patients whose liver function tests were normalized at Week 12 (LOCF) from above reference range at baseline. * p < 0.05, *** p < 0.001 vs. placebo (Fisher’s exact test). AST aspartate aminotransferase, ALT alanine aminotransferase, γ-GT γ-glutamyl transferase, ALP alkaline phosphatase, LOCF last observation carried forward

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840